JPM vs MEGI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MEGI exhibits critical fundamental weakness with a Piotroski F-Score of 1/9, indicating severe financial instability by deterministic standards. While the fund offers an attractive dividend yield of 9.89%, this is offset by a bearish technical trend (0/100) and significant insider liquidation totaling $10.46M. The current price of $15.17 trades at a premium to its growth-based intrinsic value of $14.42, suggesting limited upside potential.
Compare Another Pair
Related Comparisons
JPM vs MEGI: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and NYLI CBRE Global Infrastructure Megatrends Term Fund (MEGI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.